Cargando…

A New Prognostic Algorithm Predicting HCC Recurrence in Patients With Barcelona Clinic Liver Cancer Stage B Who Received PA-TACE

BACKGROUND: Postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE) is effective in preventing the recurrence of hepatocellular carcinoma (HCC) in patients treated with surgery. However, there is a lack of reports studying the risk factors associated with recurrence in HCC patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Shuyang, Gan, Wei, Qiao, Liang, Ye, Cheng, Wu, Demin, Liao, Boyi, Yang, Xiaoyu, Jiang, Xiaoqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566809/ https://www.ncbi.nlm.nih.gov/pubmed/34745962 http://dx.doi.org/10.3389/fonc.2021.742630

Ejemplares similares

Evaluation of D-TACE combined with endovascular brachytherapy for HCC with MPVTT
por: Huang, Wei, et al.
Publicado: (2022)

Adjuvant TACE may not improve recurrence-free or overall survival in HCC patients with low risk of recurrence after hepatectomy
por: Feng, Long-Hai, et al.
Publicado: (2023)

Identifying optimal candidates for post-TIPS patients with HCC undergoing TACE: a multicenter observational study
por: Fan, Wenzhe, et al.
Publicado: (2022)

Overexpression of PD-L1 is an Independent Predictor for Recurrence in HCC Patients Who Receive Sorafenib Treatment After Surgical Resection
por: Tan, Yifei, et al.
Publicado: (2022)

Diffuse Recurrence of Hepatocellular Carcinoma After Liver Resection: Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Monotherapy
por: Yao, Wang, et al.
Publicado: (2020)

Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study
por: Zhu, Yejing, et al.
Publicado: (2023)

Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS
por: Fan, Wenzhe, et al.
Publicado: (2021)

Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)

Correction to: Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
por: Lucatelli, Pierleone, et al.
Publicado: (2021)

Splenic Volume, an Easy-To-Use Predictor of HCC Late Recurrence for HCC Patients After Hepatectomy
por: Fang, Tongdi, et al.
Publicado: (2022)

COCH predicts survival and adjuvant TACE response in patients with HCC
por: Wang, Chen, et al.
Publicado: (2021)

TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study
por: Yang, Biao, et al.
Publicado: (2021)

The effect of lipiodol deposition in HCC after TACE on the necrosis range of PMCT
por: Sun, HongLiang, et al.
Publicado: (2017)

Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC)
por: Perfahl, H., et al.
Publicado: (2020)

CXCL1 and CXCL6 Are Potential Predictors for HCC Response to TACE
por: Kinzler, Maximilian N., et al.
Publicado: (2023)

Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis
por: Bargellini, Irene, et al.
Publicado: (2021)

Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study
por: Wang, Wei‐Jun, et al.
Publicado: (2023)

Published trials of TACE for HCC are often not registered and subject to outcome reporting bias
por: Grégory, Jules, et al.
Publicado: (2020)

The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC
por: Sun, Tao, et al.
Publicado: (2023)

Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis
por: Yao, Man, et al.
Publicado: (2022)

Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study
por: Qu, Shuping, et al.
Publicado: (2022)

Efficacy of re-resection versus radiofrequency ablation for recurrent Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma (HCC) after resection for primary HCC
por: Yin, Xieling, et al.
Publicado: (2019)

Intra-arterial ethanol embolization augments response to TACE for treatment of HCC with portal venous tumor thrombus
por: Yang, Biao, et al.
Publicado: (2018)

Treatment of Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma: liver resection versus TACE and beyond
por: Huo, Ya Ruth, et al.
Publicado: (2020)

Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis
por: Liu, Lei, et al.
Publicado: (2014)

DEB TACE for Intermediate and advanced HCC – Initial Experience in a Brazilian Cancer Center
por: Luz, Jose Hugo Mendes, et al.
Publicado: (2017)

Preoperatively predicting early response of HCC to TACE using clinical indicators and MRI features
por: Li, Zhi-Wei, et al.
Publicado: (2022)

Prognostic value of des-γ-carboxyprothrombin in patients with AFP-negative HCC treated with TACE
por: Sun, Hanyao, et al.
Publicado: (2022)

Prospective study of TACE combined with sorafenib vs TACE combined with (125)I seed implantation in the treatment of hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas
por: Zhao, Xiao-Hui, et al.
Publicado: (2022)

Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine
por: Zhou, Guanlin, et al.
Publicado: (2021)

Multidisciplinary Taiwan consensus for the use of conventional TACE in hepatocellular carcinoma treatment
por: Chang, Pi-Yi, et al.
Publicado: (2023)

Preoperative Gadoxetic Acid-Enhanced MRI Based Nomogram Improves Prediction of Early HCC Recurrence After Ablation Therapy
por: Hu, Chengguang, et al.
Publicado: (2021)

Identifying the Best Anticancer Agent Combination in TACE for HCC Patients: A Network Meta-analysis
por: Guo, Tao, et al.
Publicado: (2018)

Effects of TACE combined with precise RT on p53 gene expression and prognosis of HCC patients
por: Liu, Yupeng, et al.
Publicado: (2018)

Tumor SOCS3 methylation status predicts the treatment response to TACE and prognosis in HCC patients
por: Jiang, Bei-Ge, et al.
Publicado: (2017)

The role of muscle depletion and visceral adiposity in HCC patients aged 65 and over undergoing TACE
por: Lim, Jihye, et al.
Publicado: (2021)

Quantitative assessment of HCC wash-out on CT is a predictor of early complete response to TACE
por: Fronda, Marco, et al.
Publicado: (2021)

Repeated TACE in HCC after Fontan surgery and situs viscerum inversus: A case report
por: Gasparrini, Fulvio, et al.
Publicado: (2021)

CT-radiomics and clinical risk scores for response and overall survival prognostication in TACE HCC patients
por: Bernatz, Simon, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lvrl69jgrar7cmhgcml51f3ikc